

**CURRICULUM VITAE****BIOGRAPHICAL**

Name: David P. Greenberg, M.D.

Business Address: Vice President, Scientific and Medical Affairs  
Sanofi Pasteur US  
One Discovery Drive  
Swiftwater, PA 18370

Business Phone: (570) 957-3289

Business Fax: (570) 957-2038

E-Mail Address: [david.greenberg@sanofipasteur.com](mailto:david.greenberg@sanofipasteur.com)

Academic Appointment: Adjunct Associate Professor of Pediatrics  
University of Pittsburgh School of Medicine  
Pediatric Infectious Diseases  
Children's Hospital of Pittsburgh

---

**EDUCATION AND TRAINING****UNDERGRADUATE:**

1974-1978 University of California, Irvine, CA, B.S., Biological Sciences, 1978

**GRADUATE:**

1978-1982 Baylor College of Medicine, Houston, TX, M.D., 1982

**POST-GRADUATE:**

1982-1985 Intern/Resident, Pediatrics, University of California, Irvine, CA

1984-1985 Chief Resident, Pediatrics, Children's Hospital of Orange County,  
University of California, Irvine, CA

1985-1988 Fellowship, Pediatric Infectious Diseases, Harbor-UCLA Medical Center, University of  
California, Los Angeles, CA

---

**APPOINTMENTS AND POSITIONS****ACADEMIC:**

1985-1988 Adjunct Instructor of Pediatrics, UCLA School of Medicine, Harbor-UCLA Medical  
Center, Los Angeles, CA

1988-1995 Assistant Professor of Pediatrics, UCLA School of Medicine, Pediatric Infectious  
Diseases, Harbor-UCLA Medical Center, Los Angeles, CA

1990-1996	Associate Director, UCLA Center for Vaccine Research
1995-1996	Associate Professor of Pediatrics, UCLA School of Medicine, Pediatric Infectious Diseases, Harbor-UCLA Medical Center, Los Angeles, CA
1996-2004	Associate Professor of Pediatrics, University of Pittsburgh School of Medicine, Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, Pittsburgh, PA
1996-2004	Director, Center for Vaccine Research, Children's Hospital of Pittsburgh, Pittsburgh, PA
2004-	Adjunct Associate Professor of Pediatrics, University of Pittsburgh School of Medicine, Division of Allergy, Immunology and Infectious Diseases, Children's Hospital of Pittsburgh, Pittsburgh, PA

---

**BUSINESS:**

2004-2008	Director, Scientific and Medical Affairs, Sanofi Pasteur US
2008-2012	Senior Director, Scientific and Medical Affairs, Sanofi Pasteur US
2013-	Vice President, Scientific and Medical Affairs, and Chief Medical Officer, Sanofi Pasteur US

---

**CERTIFICATION AND LICENSURE****SPECIALTY CERTIFICATION:**

Pediatric Infectious Diseases	1994-2008
American Board of Pediatrics	1987- (Lifetime)

**MEDICAL OR OTHER PROFESSIONAL LICENSURE:**

Pennsylvania	1996-
DEA	1985-

---

**MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

American Pediatric Society	2003-
Society for Pediatric Research	1996-
Pediatric Infectious Disease Society	1990-
American Academy of Pediatrics (Fellow)	1988-
Infectious Disease Society of America (Fellow)	1988-
American Society for Microbiology (ASM)	1985-
Alpha Omega Alpha Honor Society	1982-

Phi Delta Epsilon Medical Fraternity	1978-
Phi Beta Kappa Honor Society	1978-

### HONORS

Richard E. Weitzman Memorial Research Award, Harbor-UCLA Faculty Society	1996
Resident of the Year, University of California, Irvine	1984
Intern of the Year, University of California, Irvine	1983
Alpha Omega Alpha, Baylor College of Medicine	1982
Phi Beta Kappa, University of California, Irvine	1978

### PUBLICATIONS

#### REFEREED ARTICLES (Original Research)

1. **Greenberg DP**, Ward JI, Burkart K, Christenson PD, Guravitz L, Marcy SM. Factors influencing immunogenicity and safety of two *Haemophilus influenzae* type b polysaccharide vaccines in children 18 and 24 months of age. *Pediatr Infect Dis J* 6:660-5, 1987.
2. **Greenberg DP**, Ward JI, Bayer AS. Influence of *Staphylococcus aureus* antibody on experimental endocarditis in rabbits. *Infect and Immun*, 55:3030-4, 1987.
3. Bayer AS, **Greenberg DP**, Yih J. Correlates of therapeutic efficacy in experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Chemotherapy* 34:46-55, 1988.
4. Ward JI, **Greenberg DP**, Anderson P, Burkart K, Christenson PD, Gordon L, Kayhty H, Kuo J, Vella P. Variable quantitation of *Haemophilus influenzae* type b anticapsular antibody by radioantigen binding assay. *J Clin Microbiol* 26:72-8, 1988.
5. **Greenberg DP**, Bayer AS, Cheung AL, Ward JI. Protective efficacy of protein A-specific antibody against bacteremic infection due to *Staphylococcus aureus* in an infant rat model. *Infect and Immun* 57:1113-8, 1989.
6. **Greenberg DP**, Bayer AS, Turner D, Ward JI. Antibody responses to protein A in patients with *Staphylococcus aureus* bacteremia and endocarditis. *J Clin Microbiol* 28:458-62, 1990.
7. Vadheim CM, **Greenberg DP**, Marcy SM, Froeschle J, Ward JI. Safety evaluation of PRP-D *Haemophilus influenzae* type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30,000 children. *Pediatr Infect Dis J* 9:555-61, 1990.
8. **Greenberg DP**, Vadheim CM, Bordenave N, Ziontz L, Christenson P, Waterman S, Ward JI. Protective efficacy of *Haemophilus influenzae* type b polysaccharide and conjugate vaccines in children 18 months of age and older. *JAMA* 265:987-92, 1991.
9. Vadheim CM, **Greenberg DP**, Bordenave N, Ziontz L, Christenson P, Waterman SH, Ward JI. Risk factors for invasive *Haemophilus influenzae* type b in children 18 - 60 months of age. *Am J Epidemiology* 136:221-35, 1992.

10. Calandra GB, Lukacs LJ, Jonas LC, Santosham M, Ward JI, **Greenberg DP**, Daum RS, Matthews H, Vella PP, Ryan JL. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. *Vaccine* 11 (Suppl):S58-62, 1993.
11. Vadheim CM, **Greenberg DP**, Partridge S, Jing J, Ward JI, Kaiser-UCLA Vaccine Study Group. Effectiveness and safety of an *Haemophilus influenzae* type b conjugate vaccine (PRP-T) in young infants. *Pediatrics* 92:272-9, 1993.
12. Vadheim CM, **Greenberg DP**, Eriksen E, Hemenway L, Bendana N, Mascola L, Ward JI, Kaiser-UCLA Vaccine Study Group. Eradication of *Haemophilus influenzae* type b disease in Southern California. *Arch Pediatr Adolesc Med* 148:51-6, 1994.
13. Vadheim CM, **Greenberg DP**, Eriksen E, Hemenway L, Christenson P, Ward B, Mascola L, Ward JI. Protection provided by *Haemophilus influenzae* type b conjugate vaccines in Los Angeles county: a case-control study. *Pediatr Infect Dis J* 13:274-80, 1994.
14. **Greenberg DP**, Vadheim CM, Partridge S, Chang S-J, Chiu C-Y, Ward JI, Kaiser-UCLA Vaccine Study Group. Immunogenicity of *Haemophilus influenzae* type b tetanus toxoid conjugate vaccine (PRP-T) in young infants. *J Infect Dis* 170:76-81, 1994.
15. **Greenberg DP**, Lieberman JM, Marcy SM, Wong VK, Partridge S, Chang S-J, Chiu C-Y, Ward JI. Enhanced antibody responses in infants given different sequences of heterogenous *Haemophilus influenzae* type b conjugate vaccines. *J Pediatr* 126:206-11, 1995.
16. Lieberman JM, **Greenberg DP**, Wong VK, Partridge S, Chang S-J, Chiu C-Y, Ward JI. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to *Haemophilus influenzae* type b conjugate vaccines. *J Pediatr* 126:198-205, 1995.
17. **Greenberg DP**, Vadheim CM, Marcy SM, Partridge S, Jing J, Chiu C-Y, Greene T, Margolis HS, Ward JI, Kaiser-UCLA Vaccine Study Group. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4, and 6 months of age. *Vaccine* 14:811-6, 1996.
18. **Greenberg DP**, Vadheim CM, Wong VK, Marcy SM, Partridge S, Greene T, Chiu C-Y, Margolis HS, Ward JI. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at 2, 4, and 6 months of age. *Pediatr Infect Dis J* 15:590-6, 1996.
19. Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, **Greenberg DP**, Ward JI. Epidemiology of invasive pneumococcal disease in Southern California: Implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. *J Infect Dis* 174:752-9, 1996.
20. Gerber DA, Green M, Jaffe R, **Greenberg D**, Mazariegos G, Reyes J. Cryptosporidial infections after solid organ transplantation in children. *Pediatr Transplantation* 4:50-55, 2000.
21. Miernyk KM, Parkinson AJ, Rudolph KM, Petersen KM, Bulkow LR, **Greenberg DP**, Ward JI, Brenneman G, Reid R, Santosham M. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children <2 years. *Clin Infect Dis* 31:34-41, 2000.
22. **Greenberg DP**, Wong VK, Partridge S, Chang S-J, Jing J, Howe BJ, Ward JI. Immunogenicity of a *Haemophilus influenzae* type b tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. *Pediatr Infect Dis J* 19:1135-40, 2000.
23. Lee M-S, **Greenberg DP**, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. *J Infect Dis* 184:909-13, 2001.

24. Wald ER, **Greenberg D**, Hoberman A. Short term oral cefixime therapy for treatment of bacterial conjunctivitis. *Pediatr Infect Dis J* 20:1039-42, 2001.
25. **Greenberg DP**, Pickering LK, Senders SD, Bissey JD, Howard RA, Blatter MM, Reisinger K, Pichichero ME, Howe BJ. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. *Pediatrics* 109:666-72, 2002.
26. Wadowsky RM, Castilla EA, Laus S, Kozy A, Atchison RW, Kingsley LA, Ward JI, **Greenberg DP**, and the Adult Pertussis Vaccine Efficacy Study Group. Evaluation of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* as etiologic agents of persistent cough in adolescents and adults. *J Clin Microb* 40:637-40, 2002.
27. **Greenberg DP**, Wong VK, Partridge S, Howe BJ, Ward JI. Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one and six months of age. *Pediatr Infect Dis J*, 21:769-76, 2002.
28. Zangwill KM, **Greenberg DP**, Chiu C-Y, Mendelman P, Wong VK, Chang S-J, Partridge S, Ward JI. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. *Vaccine* 21:1894-1900, 2003.
29. Yeh SH, Zangwill KM, Lee H, Chang S-J, Wong VI, **Greenberg DP**, Ward JI. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of *Neisseria meningitidis* serogroup b and nasopharyngeal carriage of *Streptococcus pneumoniae* in infants. *Vaccine* 21:2627-31, 2003.
30. Michaels MG, **Greenberg DP**, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. *Pediatr Infect Dis J* 22:504-8, 2003.
31. Hoberman A, **Greenberg DP**, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ, Zoffel LM, Fabian IA, Bernard BS, Kerr JD. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. *JAMA* 290:1608-16, 2003.
32. Jacobs RJ, **Greenberg DP**, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. *Pediatr Infect Dis J* 22:904-14, 2003.
33. Hussain SZ, Chu C, **Greenberg DP**, Orenstein D, Khan S. *Clostridium difficile* colitis in children with cystic fibrosis. *Digestive Diseases and Sciences* 49:116-21, 2004.
34. Meyerhoff A, Jacobs RJ, **Greenberg DP**, Yagoda B, Castles CG. Clinician satisfaction with vaccination visits and the role of multiple injections, results from the COVISE study (Combination Vaccines Impact on Satisfaction and Epidemiology). *Clinical Pediatr* 43:87-93, 2004.
35. Zimmerman RK, Hoberman A, Nowalk MP, Lin CJ, **Greenberg DP**, Weinberg ST, Bemm CW, Block B. Feasibility of influenza immunization for inner-city children aged 6 to 23 months. *Am J Prev Med* 27:397-403, 2004.
36. Le T, Cherry JD, Chang S-J, Knoll MD, Lee ML, Barenkamp S, Bernstein D, Edelman R, Edwards KM, **Greenberg D**, Keitel W, Treanor J, Ward JI, APERT study. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. *J Infect Dis* 190:535-44, 2004.
37. Cherry JD, Chang SJ, Klein D, Lee M, Barenkamp S, Bernstein D, Edelman R, Decker MD, **Greenberg DP**, Keitel W, Treanor J, Ward JI. Prevalence of antibody to *Bordetella pertussis* antigens in serum specimens obtained from 1,793 adolescents and adults. *Clin Infect Dis*, 39:1715-18, 2004.

38. **Greenberg DP**, Walker RE, Lee M-S, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. *J Infect Dis*, 191:1116-22, 2005.
39. Hoberman A, Paradise JL, **Greenberg DP**, Wald ER, Kearney DH, Colborn DK. Penicillin susceptibility of pneumococcal isolates causing acute otitis media in children: seasonal variation. *Pediatr Infect Dis J*, 24:115-20, 2005.
40. Lin PL, Michaels MG, Green M, Mazariegos GV, Webber SA, Lawrence KS, Iurlano K, **Greenberg DP**. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. *Pediatrics* 116:160-67, 2005
41. Nowalk MP, Zimmerman RK, Lin CJ, Ko FS, Raymund M, Hoberman A, Kearney DH, **Greenberg DP**. Parental perspectives on influenza immunization of children aged 6-23 months. *Am J Prev Med*, 29:210-14, 2005.
42. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, **Greenberg DP**, Keitel W, Barenkamp S, Bernstein DI, Edelman R, Edwards K, for the APERT study group. Efficacy of an acellular pertussis vaccine among adolescents and adults. *N Engl J Med*, 353:1555-63, 2005.
43. Black S, **Greenberg DP**. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and *Haemophilus influenzae* type b vaccine. *Expert Rev Vac* 4:793-805, 2005.
44. Meyerhoff AS, **Greenberg DP**, Jacobs RJ. Predicted effects of a new combination vaccine on childhood immunization coverage rates and vaccination activities. *Disease Management and Health Outcomes*. 13:317-26, 2005.
45. Shen K, Gladitz J, Antalis P, Dice B, Janto B, Keefe R, Hayes J, Ahmed A, Dopico R, Ehrlich N, Jocz J, Kropp L, Yu S, Nistico L, **Greenberg DP**, Barbadora K, Preston RA, Post JC, Ehrlich GD, Hu FZ. Characterization, Distribution and Expression of Novel Genes Among Eight Clinical Isolates of *Streptococcus pneumoniae*. *Infection and Immunity*. 74:321-30, 2006.
46. Ward JI, Cherry JD, Chang S-J, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, **Greenberg DP**, Barenkamp S, Bernstein DI, Edelman R, APERT study group. *Bordetella pertussis* infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized acellular pertussis vaccine trial (APERT). *Clin Infect Dis*. 43:151-7, 2006.
47. Zimmerman RK, Hoberman A, Nowalk MP, Lin CJ, **Greenberg DP**, Weinberg ST, Ko FS, Fox DE. Improving influenza vaccination rates of high risk inner-city children over 2 intervention years. *Ann Fam Med*. 4:534-540, 2006.
48. Hall-Stoodley LH, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, Forbes M, **Greenberg DP**, Dice B, Burrows A, Stoodley P, Post JC, Ehrlich GD, Kerschner JE. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. *JAMA*. 296:202-211, 2006.
49. Wendelboe AM, Njamkepo E, Bourillon A, Floret D, Gaudelus J, Gerber M, Grimprel E, **Greenberg D**, Halperin S, Liese J, Munoz-Rivas F, Teysou R, Guiso N, Van Rie A. Transmission of *Bordetella pertussis* to young infants. *Pediatr Infect Dis J*. 26:293-9, 2007.
50. Brabin L, **Greenberg DP**, Hessel L, Hyer R, Ivanoff B, Van Damme P. Current issues in adolescent immunization. *Vaccine*. 26(33):4120-4134, 2008.
51. Guerra FA, Blatter MM, **Greenberg DP**, Pichichero M, Noriega FR, Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed

equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized clinical trial. *Pediatrics*. 123(1):301-312, 2009.

52. **Greenberg DP**, Doemland M, Bettinger JA, Scheifele DW, Halperin SA, IMPACT investigators, Waters V, Kandola K. Epidemiology of pertussis and *Haemophilus influenzae* type b disease in Canada with exclusive use of a pediatric diphtheria-tetanus-acellular pertussis-inactivated poliovirus-*Haemophilus influenzae* type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. *Pediatr Infect Dis J*. 28(6):521-528, 2009.
53. Hoberman A, Paradise JL, Shaikh N, **Greenberg DP**, Kearney DH, Colborn DK, Rockette HE, Kurs-Lasky M, McEllistrem MC, Zoffel LM, Balentine TL, Barbadora KA, Wald ER. Pneumococcal resistance and serotype 19A in Pittsburgh-area children with acute otitis media before and after introduction of 7-valent pneumococcal polysaccharide vaccine. *Clinical Pediatrics*. 50(2):114-120, 2011.
54. Cherry JD, Tan T, Wirsing von König C-H, Forsyth KD, Thisyakorn U, **Greenberg D**, Johnson D, Marchant C, Plotkin S. Clinical Definitions of Pertussis: Summary of a Global Pertussis Initiative Roundtable Meeting, February 2011. *Clinical Infect Dis*. 54(12):1756-1764, 2012.
55. **Greenberg DP**, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. *Vaccine*. 31:770-776, 2013.
56. Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, **Greenberg DP**, Kirkland KB, Talbot EA, Bernstein HH. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. *Pediatr Infect Dis J*. 32(11):1257-1260, 2013.
57. Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, **Greenberg DP**, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age. *Vaccine* 31:6034-6040, 2013.
58. Robertson CA, Oster P, Johnson DR, Reinhardt A, **Greenberg DP**, Decker MD. Prevention of invasive meningococcal disease in the United States: current state of the art. *J Vaccines Vaccin* 4(8):211, 2013 (doi: 10.4172/2157-7560.1000211).
59. Tsang P, Gorse GJ, Strout CB, Sperling M, **Greenberg DP**, Ozol-Godfrey A, DiazGranados C, Landolfi V. Immunogenicity and safety of Fluzone<sup>®</sup> intradermal and high-dose influenza vaccines in older adults  $\geq 65$  years of age: A randomized, controlled, phase II trial. *Vaccine* 32(21):2507-2517, 2014.
60. **Greenberg DP**, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. *Pediatr Infect Dis J*. 33(6):630-636, 2014.
61. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, **Greenberg DP**, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *New Engl J Med*. 371(7):635-645, 2014.
62. Marshall GS, Pool V, **Greenberg DP**, Johnson DR, Sheng X, Decker MD. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. *Clinical Vaccine Immunol*. 21(11):1560-1564, 2014.
63. Chit A, Roiz J, Briquet B, **Greenberg DP**. Expected cost effectiveness of high-dose trivalent influenza vaccine in US Seniors. *Vaccine* 33:734-741, 2015.

64. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, **Greenberg DP**. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. *Vaccine* 33:4565-4571, 2015.
65. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, **Greenberg DP**. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. *Vaccine* 33:4988-4993, 2015.
66. Guevara C, Zhang C, Gaddy JA, Iqbal J, Guerra J, **Greenberg DP**, Decker MD, Carbonetti N, Starner TD, McCray PB, Mooi FR, Gomez-Duarte OG. Highly-differentiated human airway epithelial cells: a model to study host cell-parasite interactions in pertussis. *Infect Dis* 2016 (Mar;48[3]:177-88. doi: 10.3109/23744235.2015.1100323. Epub 2015 Oct 22).

### **REVIEW PUBLICATIONS (non-peer reviewed)**

1. Lieberman JM, **Greenberg DP**, Ward JI. Prevention of bacterial meningitis: vaccines and chemoprophylaxis. *Infect Dis Clin N Am* 4:703-29, 1990.
2. **Greenberg DP**, Stutman HR. Infection and Immunity to *Staphylococcus aureus* and *Haemophilus influenzae*. *Clinical Reviews in Allergy* 9:75-86, 1991.
3. **Greenberg DP**. Pediatric experience with recombinant hepatitis b vaccines and relevant safety and immunogenicity studies. *Pediatr Infect Dis J* 12:438-45, 1993.
4. **Greenberg DP**. Flexibility in scheduling of hepatitis B vaccine doses. *Pediatr Infect Dis J* 13:339-40, 1994.
5. Lieberman JM, **Greenberg DP**. Hepatitis A and B vaccines in children. *Advances in Pediatric Infectious Diseases* 11:333-63, 1996.
6. **Greenberg DP**. Transmission of hepatitis A and B in children and adolescents. *HepatoCite – International Hepatitis Update* 14:1-6, 1998.
7. **Greenberg DP**, Hoberman A. Vaccine prevention of acute otitis media. *Current Allergy and Asthma Reports* 1:358-63, 2001.
8. **Greenberg DP**. Considerations for hepatitis B as part of a combination vaccine. *Pediatr Infect Dis J* 20:S34-9, 2001.
9. **Greenberg DP**. Update on the development and use of viral and bacterial vaccines for the prevention of acute otitis media. *Allergy and Asthma Proc* 22:353-7, 2001.
10. **Greenberg DP**, Feldman S. Vaccine Interchangeability. *Clinical Pediatrics* 42:93-99, 2003.
11. Sung L, Schwartz B, Abramson J, **Greenberg D**, Edwards K, Feusner J, Allen U, Ritchey AK. Smallpox vaccination recommendations for contacts of pediatric cancer patients. *Pediatr Blood Cancer* 43:4-7, 2004.
12. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, **Greenberg D**, Guiso N, Heininger U, Schellekens J, Tan T, von König CH, and Plotkin S for the Global Pertussis Initiative. New pertussis vaccination strategies beyond infancy: Recommendations by the Global Pertussis Initiative. *Clin Infect Dis* 39:1802-9, 2004.
13. **Greenberg DP**, Wirsing von König C-H, Heininger U. Health burden of pertussis in infants and children. *Pediatr Infect Dis J*. 24:S39-43, 2005.



14. **Greenberg DP**, Caro JJ. Summary: health and economic burden of pertussis. *Pediatr Infect Dis J*. 24:S55-57, 2005.
15. Tan T, Halperin S, Cherry JD, Edwards K, Englund JA, Glezen P, **Greenberg D**, Rothstein E, Skowronski D. Pertussis immunization in the global pertussis initiative North American region: Recommended strategies and implementation considerations. *Pediatr Infect Dis J*. 24:S83-86, 2005.
16. **Greenberg DP**. Pertussis in adolescents: Increasing incidence brings attention to the need for booster immunization of adolescents. *Pediatr Infect Dis J*. 24:721-28, 2005.
17. **Greenberg DP**, Robertson CA, Gordon DM. Prevention and control of influenza and dengue through vaccine development. *Pediatric Annals*. 48(8):172-177, 2013.

#### **LETTER TO EDITOR (non-peer reviewed)**

1. Meyerhoff AS, **Greenberg DP**. 2-dose hepatitis vaccination versus 3-dose regimen. *Pediatrics*. 109:1183-4, 2002.
2. André P, Johnson DR, **Greenberg DP**, Decker MD. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not supported when data are stratified by age. *Clinical Infect Dis*. 57:1658-1660, 2013.
3. Decker MD, Hosbach P, Johnson DR, Pool V, **Greenberg DP**. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine. *J Infect Dis*. 211:497-498, 2014.
4. Decker MD, DiazGranados CA, Chit A, Hosbach P, Robertson CA, **Greenberg DP**. Regarding primary care patients who received influenza vaccine at Veteran Health Administration medical centers. *Clinical Infect Dis*. 61:1344-13-45, 2015.

#### **OTHER INVITED REVIEWS (non-peer reviewed)**

1. **Greenberg DP**. Recent developments in combination vaccines: clinical implications. Guest editor. *Pediatr Infect Dis J* 20:S5-S62, 2001.
2. **Greenberg DP**. Health burden of pertussis: rates and clinical spectrum of morbidity, hospitalization, complications and mortality in infants and children. Global Pertussis Initiative. [www.pertussis.net](http://www.pertussis.net), 2001.
3. **Greenberg DP**, Rothstein E. Strategy Summary: Universal immunization of adolescents. Global Pertussis Initiative. [www.pertussis.net](http://www.pertussis.net), 2002.

#### **BOOK CHAPTERS (non-peer reviewed)**

1. **Greenberg DP**. Chapter 6, Combination Vaccines. In: Marshall GS (ed). *Vaccine Handbook: A Practical Guide for Clinicians*. Lippincott Williams & Williams, Philadelphia, 2004. Topic included in Chapter 6: DTaP/Hepatitis B/IPV vaccine.
2. **Greenberg DP**. Chapter 8, Vaccines for Specialized Use. In: Marshall GS (ed). *Vaccine Handbook: A Practical Guide for Clinicians*. Lippincott Williams & Williams, Philadelphia, 2004. Topics included in Chapter 8: Adenovirus, Bacille Calmette-Guérin, Cholera, Hepatitis A, Japanese encephalitis, Lyme disease, Meningococcal polysaccharide, Rabies, Typhoid and Yellow fever.
3. **Greenberg DP**. Chapter 10, Vaccines in Development for General Use. In: Marshall GS (ed). *Vaccine Handbook: A Practical Guide for Clinicians*. Lippincott Williams & Williams, Philadelphia,

2004. Topics included in Chapter 10: 2000 Institute of Medicine report, New combinations (DTaP-Hib-IPV, MMRV, other combinations), Cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Human immunodeficiency virus, Human papillomavirus, Live-attenuated influenza, Meningococcal polysaccharide conjugate, Increased valency pneumococcal polysaccharide conjugates, Parainfluenza virus, Respiratory syncytial virus and Rotavirus.

4. Posfay-Barbe KM, **Greenberg DP**. Immunization. In: Fireman P (ed). Atlas of Allergies and Clinical Immunology. Third Edition. Philadelphia, Mosby Elsevier, pages 379-396, 2006.

### **ABSTRACTS**

1. **Greenberg DP**, Ward JI, Christenson PD, Gordon L, Kayhty H, Kuo J, Anderson P. Variability in quantitation of *Haemophilus influenzae* type b anticapsular antibody (anti-PRP) by radioimmunoassay (RIA). Program and Abstracts of the 26th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), p. 133, Abst. 209 (presented), 1986.
2. Bayer AS, **Greenberg DP**. Pefloxacin (Peflox) vs. Vancomycin (Vanco) in experimental endocarditis (IE) due to methicillin-resistant *Staphylococcus aureus* (MRSA). Program and Abstracts of the 26th ICAAC, p. 147, Abst. 283 (presented), 1986.
3. **Greenberg DP**, Burkart K, Christenson PD, Marcy SM, Guravitz L, Ward JI. Immunogenicity and safety of two *Haemophilus influenzae* type b capsular polysaccharide vaccines in children 18 and 24 months of age. Clinical Research 35: 219A (presented), 1987.
4. **Greenberg DP**, Bayer AS, Nast CC, Ward JI. Effect of whole cell immunization on the development of *Staphylococcus aureus* endocarditis in rabbits. Clinical Research 35: 219A, 1987.
5. **Greenberg DP**, Cheung AL, Peters J, Bayer AS, Ward JI. Opsonophagocytic (O-P) and protective activity of rabbit and human antibodies to *Staphylococcus aureus* (SA). Program and Abstracts of the 27th ICAAC, p. 185, Abst. 510 (presented), 1987.
6. **Greenberg DP**, Bayer AS, Ward JI. Evaluation of staphylococcal protein A (SpA) antibody levels in patients with *Staphylococcus aureus* (SA) bacteremia and endocarditis by ELISA. Program and Abstracts of the 27th ICAAC, p. 225, Abst. 736 (presented), 1987.
7. **Greenberg DP**, Musser JM, Bayer AS, Selander RK, Ward JI. Genetic and epidemiologic characterization of *Staphylococcus aureus* (SA) with multilocus enzyme electrophoresis. Program and Abstracts of the 28th ICAAC, p. 285, Abst. 990 (presented) 1988.
8. **Greenberg DP**, Vadheim CM, Marcy SM, Ward JI. Safety of *H.influenzae* type b (Hib) conjugate vaccine (PRP-D) in 15,713 children 18-60 months of age. Pediatric Research 25:179A, 1989.
9. **Greenberg DP**, Vadheim CM, Marcy SM, Ward JI. Safety and efficacy of *H.influenzae* type b conjugate vaccine (PRP-D) in children 18-60 months of age. Program and Abstracts of the 29th ICAAC, p. 172, Abst. 431 (presented), 1989.
10. **Greenberg DP**, Vadheim CM, Christenson P, Bordenave N, Ziontz L, Waterman S, Ward JI. Protective efficacy of *H.influenzae* type b (Hib) vaccines (PRP and PRP-D) in children 18 to 59 months of age. Pediatric Research 27:171A (presented), 1990.
11. Vadheim CM, **Greenberg DP**, Bordenave N, Ziontz L, Waterman S, Ward JI. Risk factors for *H.influenzae* type b (Hib) disease in children 18-59 months of age in LA County. Pediatric Research 27:99A, 1990.

12. **Greenberg DP**, Marcy SM, Wong V, Berkowitz C, Burkart K, Ward JI. Comparative immunogenicity of *H. influenzae* type b (Hib) vaccines in children 18 months of age. *Pediatric Research* 27:156A, 1990.
13. **Greenberg DP**, Bundy D, Jing J, Meschievitz C, Marcy SM, Ward JI. Comparison of the safety and immunogenicity of an acellular pertussis (BIKEN) vaccine (AC-DTP) with whole cell pertussis vaccine (WC-DTP) in infants 2 to 6 months of age. Program and Abstracts of the 30th ICAAC, p. 188, Abst. 611 (presented), 1990.
14. Vadheim CM, **Greenberg DP**, Bordenave N, Ziontz L, Waterman S, Ward JI. Risk factors for and effect of vaccination on invasive *H. influenzae* type b (Hib) disease in children 18 - 59 months of age. Program and Abstracts of the 30th ICAAC, p. 276, Abst. 1141 (presented), 1990.
15. **Greenberg DP**, Vadheim CM, Marcy SM, Wong V, Margolis H, Ward JI. Safety and immunogenicity of two recombinant hepatitis B vaccines given to 5,000 infants as part of routine immunization at 2, 4, and 6 months of age. Program and Abstracts of the 31st ICAAC, p. 314, Abst. 1290 (presented), 1991.
16. **Greenberg DP**, Vadheim CM, Marcy SM, Ward JI, Kaiser-UCLA Hib Vaccine Study Group. Evaluation of the safety, immunogenicity, and efficacy of *Haemophilus b* (Hib) PRP-T conjugate vaccine in a prospective, randomized, and placebo-controlled trial in young infants. Program and Abstracts of the 31st ICAAC, p. 109, Abst. 65 (presented), 1991.
17. **Greenberg DP**, Stutman HR, Marks MI, Patel TD, Karakawa WW, Ward JI. Immune responses to *Staphylococcus aureus* (SA) in young children with Cystic Fibrosis (CF). Program and Abstracts of the 32nd ICAAC, p. 169, Abst. 352 (presented), 1992.
18. **Greenberg DP**, Vadheim CM, Marcy SM, Wong V, Margolis H, Greene T, Ward JI. Comparative safety and immunogenicity of two recombinant hepatitis B (HBV) vaccines given to infants at 2, 4, and 6 months of age. Program and Abstracts of the 32nd ICAAC, p. 264, Abst. 920 (presented), 1992.
19. Vadheim CM, **Greenberg DP**, Eriksen E, Hemenway L, Mascola L, Marcy SM, Ward JI. Reduction of Hib disease in Southern California, 1983-1991. Program and Abstracts of the 32nd ICAAC, p. 398, Abst. 1726 (presented), 1992.
20. **Greenberg DP**, Vadheim CM, Partridge S, Chang S-J, Chiu C-Y, Ward JI, Kaiser-UCLA Vaccine Study Group. Post-licensure evaluation of PRP-OMP vaccine lots with less than expected immunogenicity. *Pediatric Research* 33:169A (presented), 1993.
21. **Greenberg DP**, Lieberman JM, Marcy SM, Wong VK, Partridge S, Chang S-J, Chiu C-Y, Ward JI. Safety and immunogenicity of mixed sequences of *Haemophilus influenzae* type b (HIB) conjugate vaccines in infants. *Pediatric Research* 33:169A, 1993.
22. Lieberman JM, **Greenberg DP**, Wong VK, Marcy SM, Partridge S, Chang S-J, Chiu C-Y, Ward JI. Does newborn immunization with diphtheria-tetanus toxoid (DT) prime for enhanced antibody responses to *H. influenzae* type b (HIB) conjugate vaccines? *Pediatric Research* 33:174A (presented), 1993.
23. **Greenberg DP**, Lieberman JM, Marcy SM, Wong VK, Partridge S, Chang S-J, Chiu C-Y, Ward JI. Improved antibody (Ab) responses in infants given mixed sequences of *Haemophilus influenzae* type b (Hib) conjugate vaccines. Program and Abstracts of the 33rd ICAAC, p. 175, Abst. 305 (presented), 1993.
24. Vadheim CM, **Greenberg DP**, Hemenway L, Eriksen E, Christenson P, Mascola L, Ward JI. Risk factors for *H. influenzae* type b (Hib) disease in children after introduction of routine immunization in LA county. Program and Abstracts of the 33rd ICAAC, p. 421, Abst. 1653, (presented), 1993.

25. Vadheim CM, **Greenberg DP**, Eriksen E, Hemenway L, Ward B, Mascola L, Ward JI. Spectrum of *Haemophilus influenzae* disease in adults in L.A. county before and after routine pediatric vaccination. Program and Abstracts of the 33rd ICAAC, p. 421, Abst. 1654, (presented), 1993.
26. Ward JI, Vadheim CM, **Greenberg DP**, Eriksen E, Hemenway L, Christenson P, Ward B, Mascola L. Risk of invasive *H. influenzae* type b (Hib) disease during a period of rapidly decreasing disease incidence. Abstracts of the Am Epidemiological Society, 1994.
27. Chiu SS, **Greenberg DP**, Marcy SM, Wong VK, Chang SJ, Chiu CY, Ward JI. Mucosal antibody responses in infants following immunization with *Haemophilus influenzae* type b (Hib) conjugate vaccines. Pediatric Research 35:10A (presented), 1994.
28. Zangwill KM, Vadheim CM, Eriksen E, **Greenberg DP**, Marcy SM, Austrian R, Ward JI. Epidemiology of invasive pneumococcal disease in the Southern California Kaiser-Permanente patient population (SCKP). Pediatric Research 35:123A (presented), 1994.
29. Mendelman PM, Block S, Hedrick J, Anderson E, Keyserling H, Yogev R, **Greenberg D**, Rusk C, Shadle C, Loy D, Chung M, Stallworth M, Calandra G, Matthews H, Ward J, Feeley L, Donnelly J, Liu M, Ellis R, Ryan JI. Immunogenicity of a 7 valent pneumococcal conjugate vaccine in 2 month old infants. Pediatric Research 35:187A (presented), 1994.
30. Zangwill K, Melamed R, Ward J, Marcy S, Partridge S, Abramson O, **Greenberg DP**, Dagan R. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine among children 12-24 months of age. Pediatric Research 37:191A (presented), 1995.
31. Eriksen E, Vadheim CM, Hemenway L, **Greenberg DP**, Bendana N, Ward B, Mascola L, Ward JI. Declining invasive *Haemophilus influenzae* (HI) disease in non-immunized age groups, 1988-94. Abstracts of the Am Public Health Assoc, p. 159 (presented), 1995.
32. **Greenberg DP**, Wong VK, Partridge S, Howe BJ, Jing J, Ward JI. Evaluation of a new combination vaccine that incorporates diphtheria-tetanus-acellular pertussis (DTaP), hepatitis B (HB) and *Haemophilus influenzae* type b (Hib) conjugate (PRP-T) vaccines. Program and Abstracts of the 35th ICAAC, p.170, Abst. G70 (presented), 1995.
33. Chiu SS, **Greenberg DP**, Partridge S, Chang SJ, Chiu CY, Marcy SM, Ward JI. Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PPCV) in healthy toddlers. Abstracts of the 35th ICAAC, p. 171, Abst. G71 (presented), 1995.
34. **Greenberg DP**, Marcy SM, Wong VK, Vadheim CM, Partridge S, Krause D, Howe BJ, Margolis HS, Ward JI. Evaluation of recombinant hepatitis B vaccines given to infants at 2, 4, and 6 months of age in the U.S. IX Triennial International Symposium on Viral Hepatitis and Liver Disease (presented), Rome, Italy, 1996.
35. Zangwill KM, **Greenberg DP**, Wong VK, Chang S-J, Partridge S, Ward JI. Safety and immunogenicity of two lots of pneumococcal conjugate vaccine in infants. Pediatric Research 39:188A (presented), 1996.
36. **Greenberg DP**, Wong VK, Partridge S, Chang SJ, Howe BJ, Ward JI. Immunogenicity of a booster dose of Hib conjugate vaccine in children with impaired immune responses following primary vaccination with DTaP-Hep B-PRP-T vaccine. Abstracts of the 36th ICAAC p.154, Abst. G61 (presented), 1996.
37. Miernyk KM, Rudolph KR, Parkinson AJ, Petersen K, Bulkow LR, **Greenberg DP**, Ward JI. Response to the heptavalent pneumococcal conjugate vaccine in Alaska native and non-native infants. Program and Abstracts of the Infectious Diseases Society of America (IDSA) 34th Annual Meeting, p.88, Abst. 281 (presented), 1996.

38. **Greenberg DP**, Zangwill KM, Partridge S, Chang S-J, Wong VK, Curry ES, Ward JI. Factors influencing the immunogenicity of a pneumococcal conjugate vaccine in infants. *Pediatric Research* 41:121A (presented), 1997.
39. Huang H-F, **Greenberg DP**, Wong VK, Chiu SS, Partridge S, Chang S-J, Ward JI. Mucosal immunity in infants immunized with *H. influenzae* type b (Hib) conjugate vaccines. *Pediatric Research* 41:10A (presented), 1997.
40. **Greenberg DP**, Wong VK, Partridge S, Howe BJ, Ward JI. Safety and immunogenicity of a combination DTPa-hepatitis B vaccine (DTPa-Hep B) administered to infants at 2, 4 and 6 months of age. Abstracts of the 35<sup>th</sup> Annual IDSA Meeting (presented), September, 1997.
41. **Greenberg DP**, Bissey J, Blatter M, Howard R, Pickering L, Senders SD, Smail K, Howe BJ. Evaluation of the interchangeability of two different diphtheria-tetanus-acellular pertussis (DTaP) vaccines administered to healthy infants at 2, 4, and 6 months of age. Abstracts of the 36<sup>th</sup> Annual IDSA Meeting, Abst. 697, (presented), October 1998.
42. **Greenberg DP**, Yeh S, Yogev R, Reisinger KS, Ward JI, Blatter MM, Holmes S, Mendelman PM, Coelingh KL, Cho I. Evaluation of the safety, immunogenicity and virus shedding of a live intranasal bovine parainfluenza virus type 3 (PIV3) vaccine in infants. Second Annual Conference on Vaccine Research, Abst. S15, (presented), March, 1999.
43. Yeh S, Zangwill K, Lee H, Chang S-J, **Greenberg DP**, Partridge S, Wong VK, Curry E, Ward J. Nasopharyngeal carriage of *Streptococcus pneumoniae* conjugate vaccine. Second Annual Conference on Vaccine Research, Abst. S3, (presented), March, 1999.
44. **Greenberg DP**, Yeh S, Yogev R, Reisinger KS, Ward JI, Blatter MM, Holmes S, Mendelman PM, Coelingh KL, Cho I. Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants. *Pediatr Res* 45:161A (presented), 1999.
45. Meyerhoff AS, **Greenberg DP**, Jacobs RJ. Cost benefit analysis of DTPa-HepB-IPV pentavalent vaccine. *Pediatr Res* 47:210A (presented), 2000.
46. Lee MS, **Greenberg DP**, Yeh S, Yogev R, Reisinger KS, Ward JI, Cho I, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. Abstracts of the 4<sup>th</sup> Annual Conference on Vaccine Research (presented), 2001.
47. Hoberman A, **Greenberg DP**, Paradise JL, Rockette HE, Lave J, Kearney D, Colborn DK, Kurs-Lasky M, Haralam MA, Byers C, Zoffel L, Bernard B. Efficacy of influenza vaccine in the prevention of acute otitis media (AOM). *Pediatr Res*, 49:165A, 2001.
48. Meyerhoff AS, **Greenberg DP**, Jacobs RJ. Cost effectiveness of 3-dose versus 2-dose adolescent hepatitis B vaccination regimens. *Pediatr Res*, 49:151A (presented), 2001.
49. Wadowsky RM, Castilla EA, Laus S, Kozy A, Atchison RW, Kingsley LA, Ward JI, **Greenberg DP**. Evaluation of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* as etiologic agents of persistent cough in adolescents and adults. Abstracts of the American Society for Microbiology, Abst. C-322 (presented), 2001.
50. Meyerhoff AS, **Greenberg DP**, Jacobs RJ. Cost effectiveness of 3-dose versus 2-dose adolescent hepatitis B vaccination regimens. 35<sup>th</sup> National Immunization Conf, (presented), Atlanta, GA, 2001.
51. Michaels MG, Sabo D, Wald ER, **Greenberg DP**. Ganciclovir treatment of children with congenital cytomegalovirus. Infectious Disease Society of America, (presented), 2002.

52. Meyerhoff AS, Jacobs RJ, **Greenberg DP**, Yagoda B, Castles CG. Clinician satisfaction with vaccination visits and the role of multiple injections: Results from the COVISE Study (Combination Vaccines Impact on Satisfaction and Epidemiology). *Pediatr Res* 53(4):230A (presented), 2003.
53. Meyerhoff AS, **Greenberg DP**, Baswell DLP, Jacobs RJ, Lemley EM. Effects of DTaP-HepB-IPV vaccine on office vaccination costs: Results from the COVISE Study (Combination Vaccines Impact on Satisfaction and Epidemiology). *Pediatr Res* 53(4):230A (presented), 2003.
54. Lin CJ, Nowalk MP, Zimmerman RK, Hoberman A, **Greenberg DP**, Weinberg ST. Feasibility of influenza immunization for children 6-23 months in the inner city. 38<sup>th</sup> National Immunization Conference, (presented), 2004.
55. Meyerhoff AS, **Greenberg DP**, Jacobs RJ. Effects of a new combination vaccine on childhood immunization coverage rates. *Pediatr Res* 55:257A (presented), 2004.
56. **Greenberg DP**, Scheifele D, Noriega F, Mills E, Tomovici A. Immunogenicity of Pentacel™ when administered as a fourth dose at 15 to 18 months of age. Pediatric Academic Societies Annual Meeting, (presented), 2004.
57. Pichichero M, Edwards KM, **Greenberg D**, Mills E. Safety of tetanus-diphtheria-acellular pertussis (Tdap) vaccine in adolescents. Abstracts of the 44th ICAAC, G-546, p. 256 (presented), 2004.
58. Herz A, Black S, Shinefield H, Noriega F, **Greenberg D**. Safety of combined DTaP-IPV + PRP-T vaccine (Pentacel™) administered at 2, 4, 6, and 15 to 18 months of age. Pediatric Academic Societies Annual Meeting, Abstract #1388 (presented), Washington DC, May 14-17, 2005.
59. Noriega F, **Greenberg DP**, Tsang PH, Blisard RJ, Maus D, Nyberg J, DeTora L, Decker MD, Pentacel vaccine study group. Effect of pneumococcal conjugate vaccine (PCV-7) on antibody responses to concomitantly administered PENTACEL™ (DTaP-IPV//PRP-T) or licensed equivalent vaccines. 43<sup>rd</sup> Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 981 (presented), San Francisco, Oct 6-9, 2005.
60. Noriega F, Tomovici A, Jemiolo D, **Greenberg DP**, P3T06 study group. Safety and immunogenicity comparison of a fourth dose of DTaP-IPV//PRP-T (Pentacel™) to the separate administration of DAPTACEL® and ActHIB®. 43<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 985 (presented), San Francisco, Oct 6-9, 2005.
61. Black S, Ray P, Lewis E, Hansen J, Decker MD, Greenberg DP. Lower reactogenicity of two different DTaP preparations in young children versus combined DTaP-IPV-Hepatitis B. 43<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), (accepted), San Francisco, Oct 6-9, 2005 and 5<sup>th</sup> Pediatric Infectious Diseases Conference, (presented), Napa, CA, Oct. 10-11, 2005.
62. **Greenberg DP**, Doemland ML, Lavigne P. Impact of Pentacel™ (DTaP-IPV//PRP-T) on the epidemiology of invasive Hib disease and pertussis in Canada. 5<sup>th</sup> Pediatric Infectious Diseases Conference, (presented), Napa, CA, Oct. 10-11, 2005.
63. Noriega F, Tsang P, Jemiolo D, Voloshen T, **Greenberg DP** and the Pentacel Investigators Study Group. Immunogenicity of a four dose series of DTaP-IPV//PRP-T (Pentacel™). 5<sup>th</sup> Pediatric Infectious Diseases Conference, (presented), Napa, CA, Oct. 10-11, 2005.
64. **Greenberg DP**, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine (QIV) containing two A and two B Strains. 48<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 870 (presented), Vancouver, Canada, Oct 21-24, 2010 and IDSA's Seasonal and Pandemic Influenza 2010, Abstract 13, Arlington, VA, January 27-28, 2011.

65. **Greenberg DP**, Falsey AR, Gorse GJ, Fling JA, Poling TL, Strout CB, Tsang PH. Phase III clinical trial comparing the safety and immunogenicity of Fluzone(R) vaccine administered intradermally with standard Fluzone vaccine administered intramuscularly in adults 18-64 years of age. IDSA's Seasonal and Pandemic Influenza 2011, Abstract 8, Arlington, VA, January 27-28, 2011.
66. **Greenberg DP**, Robertson C, Talbot HK, Decker MD. Safety and Immunogenicity of a Quadrivalent Inactivated Influenza Vaccine (QIV) Containing Two A and Two B Strains among Persons  $\geq$  65 Years of Age. 4<sup>th</sup> ESWI Influenza Conference, Abstract A506P (presented), Malta, September 11-14, 2011.
67. **Greenberg DP**, Robertson C, Talbot HK, Decker MD. Safety and Immunogenicity of a Quadrivalent Inactivated Influenza Vaccine (QIV) Containing Two A and Two B Strains among Persons  $\geq$  65 Years of Age. 49<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 544 (presented), Boston, October 20-23, 2011.
68. Tsang P, Gorse G, Strout CB, Sperling M, DiazGranados C, **Greenberg D**, Ozol-Godfrey A, Landolfi V, Denis M. Immunogenicity and safety of a high dose influenza vaccine in the elderly compared with Fluzone<sup>®</sup> in young adults and the elderly. 49<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 543 (presented), Boston, October 20-23, 2011.
69. **Greenberg DP**, Robertson C, Senders S, Decker MD. Safety and Immunogenicity of a Quadrivalent Inactivated Influenza Vaccine (QIV) Containing Two A and Two B Strains in Children. Pediatric Academic Societies Annual Meeting, Abstract 4350.7 (presented), Boston, May 1, 2012.
70. **Greenberg DP**, Robertson CA, Landolfi V, Bhaumik A, Colfer AM, Decker, MD. Report of three phase II/III clinical trials of quadrivalent inactivated influenza vaccine (QIV) containing two A and two B strains among children, adults, and seniors. IDWeek (IDSA), Abstract 1792 (presented), San Diego, October 17-21, 2012.
71. Robertson CA, **Greenberg DP**, Decker MD. Safety and Immunogenicity Comparison of 2011-2012 High-Dose and Standard Intramuscular Influenza Vaccines in Older Adults. IDWeek (IDSA), Abstract 1527 (presented), San Diego, October 17-21, 2012.
72. Englund JA, Edwards KM, Campbell JD, Walter EC, Creech CB, Johnson DR, **Greenberg DP**, Decker MD. Safety and Immunogenicity of Adacel<sup>®</sup> vs Boostrix<sup>®</sup> in Adolescents. Pediatric Academic Societies Annual Meeting, Abstract 1537.496 (presented), Washington, D.C., May 4, 2013.
73. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, **Greenberg DP**. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. AMDA Long Term Care Medicine – 2014 (presented), Nashville, TN, February 27 – March 2, 2014.
74. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, **Greenberg DP**. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. American Geriatrics Society Meeting (presented), Orlando, FL, May 15–17, 2014.
75. Talbot HK, Dunning AJ, Landolfi V, **Greenberg DP**, Robertson CA, DiazGranados CA. Disease modulation in older adults vaccinated with high-dose versus standard-dose influenza vaccine. IDSA/IDWeek (presented), Philadelphia, PA, October 8-12, 2014.

## **PROFESSIONAL ACTIVITIES**

### **EDITORIAL SERVICES TO SCHOLARLY PUBLICATIONS**

- 2001 Guest Editor, "Recent Developments in Combination Vaccines: Clinical Implications", Supplement to Pediatric Infectious Disease Journal, 2001
- 2001 American Academy of Pediatrics, Committee on Infectious Diseases, Contributing editor, 26<sup>th</sup> (2003) edition of the Red Book
- 2000-04 Course Director, International Immunocompromised Host Society, "Mycology Initiative", 8 review monographs: 1) Opportunistic Fungi in the Immunocompromised Patient, 2001; 2) Cancer and Bone Marrow Transplantation; 3) Solid Organ Transplantation; 4) Nosocomial Candidiasis; 5) Human Immunodeficiency Virus (HIV); 6) Pediatric Fungal Infections; 7) Aspergillosis; 8) Endemic Mycoses and Emerging Fungi
- 1998 American Academy of Pediatrics, Committee on Infectious Diseases, Contributing editor, 25<sup>th</sup> (2000) edition of the Red Book
- 1995 American Academy of Pediatrics, Committee on Infectious Diseases, Contributing editor, 24<sup>th</sup> (1997) edition of the Red Book
- 1988- Peer Reviewer:
- |                                      |                       |
|--------------------------------------|-----------------------|
| Journal of Infectious Diseases       | Journal of Pediatrics |
| Infection and Immunity               | Vaccine               |
| Editorial Board (1996-2001)          | JAMA                  |
| Pediatric Infectious Disease Journal | Pediatric Research    |

### **ADVISORY AND CONSULTING ACTIVITIES RELATED TO RESEARCH**

- 2002 (b) (4) Vaccine Advisory Board, (b) (4)
- (b) (4) FDA Vaccines and Related Biological Products Advisory Committee, Consultant to (b) (4), Advisory Committee meeting to review the safety and immunogenicity of (b) (4) vaccine
- 1999-2002 Medical Advisory Committee for (b) (4) Vaccine (b) (4)
- 1998-2001 Medical Advisory Board, (b) (4)
- 1996-2004 Vaccine Advisory Committee for Children's Hospital of Pittsburgh and Children's Community Care Practices
- 1995-2000 Pediatric Medicine and Immunization Consultant, (b) (4).
- (b) (4) FDA Vaccines and Related Biological Products Advisory Committee, Consultant to (b) (4), Advisory Committee meeting to review the safety and immunogenicity of (b) (4) vaccine administered to infants at 2, 4, and 6 months of age
- (b) (4) FDA Vaccines and Related Biological Products Advisory Committee, Consultant to (b) (4), Advisory Committee meeting to review the licensing requirements for (b) (4) vaccines

### **NIH/NIAID AND CDC REVIEW COMMITTEES:**

- 5/96 NIAID/NIH Review Committee for Contract Proposals  
Maternal Immunization for the Prevention of Infectious Diseases in Neonates and Infants
- 11/93 Centers for Disease Control and Prevention



Reviewer of "Hepatitis B: Virology, epidemiology, disease, and prevention, and an overview of viral hepatitis", published in Am J Preventive Medicine 10 (Suppl):45-55, 1994

2/91 NIAID/NIH Protocol Review Committee  
Development of a research study to evaluate the interchangeability of different Hib vaccines in infancy for NIH Vaccine Evaluation Units

### **DATA SAFETY MONITORING BOARDS:**

2003-09	NIAID A phase II randomized, double-blinded, comparative clinical trial for a group B <i>Streptococcus</i> serotype III-tetanus toxoid (GBS-III-TT) vaccine to prevent vaginal acquisition of GBS type III.	Member, DSMB
2000-04	(b) (4) (b) (4)	(b) (4)
1999-2002	Aventis Pasteur Safety and immunogenicity of DTaP-Hep B-Hib-IPV vaccine in infants at 2, 4, 6, and 12 months of age	Member, DSMB
1998-2000	(b) (4) (b) (4)	(b) (4)
1994	Centers for Disease Control and Prevention Safety and immunogenicity of hepatitis A vaccine in infants	Member, DSMB

### **SERVICE:**

#### **ADMINISTRATIVE ACTIVITIES**

##### **UNIVERSITY AND MEDICAL SCHOOL**

1998-2004 University of Pittsburgh School of Medicine Student Applicant Interview Committee

##### **HOSPITAL / DEPARTMENT / DIVISION**

2000-04 Chair, Clinical Research Committee, Children's Community Care  
2000-01 Chair, Search Committee, Chief of Endocrinology  
1999-2004 Member, Human Rights Committee (IRB), Children's Hospital of Pittsburgh  
1998-99 Member, Ambulatory Section Chief Search Committee  
1996-2004 Vaccine Advisory Committee, Children's Community Care  
1996-2004 Director, Center for Vaccine Research, Children's Hospital of Pittsburgh  
1996-2004 Infection Control Committee, Children's Hospital of Pittsburgh  
1985-96 Infection Control Committee, Harbor-UCLA Medical Center  
1991-96 Los Angeles County Department of Health Services, Acute Communicable Disease Advisory Committee  
1989-92 Harbor-UCLA Research and Education Institute Human Subjects Committee, Vice Chair

1988-96 Associate Director, UCLA Center for Vaccine Research  
1988-96 AAP - California Chapter 2 Infectious Disease Committee

**RESEARCH INTERESTS:**

Phase I- IV safety and immunogenicity evaluations of bacterial and viral vaccines:

*Haemophilus influenzae* type b (Hib)

DTaP and Tdap vaccines (infants, children, adolescents, adults)

Polio (IPV)

Hepatitis B vaccine

Combination vaccines (DTaP-Hib, DTaP-IPV/Hib, DTaP-HepB-IPV)

Influenza (inactivated and live cold adapted vaccines, high-dose vaccine for persons  $\geq 65$  years of age, intradermal influenza vaccine, and quadrivalent influenza vaccines)

Pre-pandemic and pandemic H5N1 influenza vaccines (adjuvanted and non-adjuvanted)

H1N1 pandemic influenza vaccine

Meningococcal conjugate vaccine

Community surveillance of vaccine-preventable infectious diseases and effectiveness of vaccines against:

Influenza

Invasive Hib disease

Pertussis

*Neisseria meningitidis*